Thus, targeting PTBP2-BNIP3-mediated autophagy by genetic ablation of PTBP2 or pharmacological inhibition of PTBP2 can reduce the disease severity in the CML cells. Here, BNIP3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.